US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zenas BioPharma Inc.

11.63

+0.43003.84%

Volume:134.07K

Turnover:1.53M

Market Cap:486.13M

PE:-0.98

High:11.75

Open:10.86

Low:10.55

Close:11.20

Loading ...

Overview Company News Filings

Zenas BioPharma Initiated at Outperform by Wolfe Research

Wolfe Research Initiates Coverage on Zenas BioPharma With Outperform Rating, $19 Price Target

MT Newswires Live

Zenas BioPharma initiated with an Outperform at Wolfe Research

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

Zenas BioPharma initiated with a Buy at H.C. Wainwright

HC Wainwright Initiates Zenas BioPharma at Buy With $30 Price Target

MT Newswires Live

Zenas BioPharma Initiated at Buy by HC Wainwright & Co.

Zenas Biopharma, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS

Zenas BioPharma Is Maintained at Overweight by Morgan Stanley

Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley

Zenas Biopharma Inc : Morgan Stanley Cuts Target Price to $35.00 From $40.00

THOMSON REUTERS

Strategic Shift and Positive Outlook Justify Buy Rating for Zenas BioPharma, Inc.

Zenas BioPharma’s Promising Pipeline and Strategic Moves Earn Buy Rating

Zenas BioPharma reports Q3 EPS ($5.02), consensus ($9.33)

Press Release: Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

Zenas BioPharma initiated with a Buy at Rodman & Renshaw

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ZBIO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":11.63,"timestamp":1746043161986,"preClose":11.2,"halted":0,"volume":134065,"delay":0,"floatShares":20878693,"shares":41799336,"eps":-11.893967,"marketStatus":"Trading","change":0.43,"latestTime":"04-30 15:59:23 EDT","open":10.86,"high":11.75,"low":10.5498,"amount":1526740.666095,"amplitude":0.107161,"askPrice":11.65,"askSize":358,"bidPrice":11.57,"bidSize":82,"shortable":3,"etf":0,"ttmEps":-11.893967,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":11.2,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":11.2,"preClose":11.2,"latestTime":"08:45 EDT","volume":302,"amount":3406.6496939999997,"timestamp":1746017141331},"volumeRatio":1.059101},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","floatShares":20878693,"roa":"-46.76%","roe":"-93.22%","lyrEps":-11.893967,"volumeRatio":1.059101,"shares":41799336,"dividePrice":0.04783,"high":11.75,"amplitude":0.107161,"preClose":11.2,"low":10.5498,"week52Low":5.83,"pbRate":"1.56","psRate":"97.23","week52High":26.2508,"institutionHeld":0,"latestPrice":11.63,"committee":-0.627273,"eps":-11.893967,"divideRate":0.004113,"volume":134065,"delay":0,"ttmEps":-11.893967,"open":10.86,"prevYearClose":8.19,"prevWeekClose":10.02,"prevMonthClose":7.9,"prevQuarterClose":7.9,"fiveDayClose":9.91,"twentyDayClose":7.6,"sixtyDayClose":7.41},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZBIO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2508026459","title":"Zenas BioPharma Initiated at Outperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2508026459","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508026459?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:26","pubTimestamp":1738675560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 04, 2025 08:26 ET (13:26 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"gpt_icon":0},{"id":"2508455597","title":"Wolfe Research Initiates Coverage on Zenas BioPharma With Outperform Rating, $19 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2508455597","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508455597?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:44","pubTimestamp":1738673073,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (ZBIO) has an average rating of Buy and mean price target of $33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO"],"gpt_icon":0},{"id":"2508175688","title":"Zenas BioPharma initiated with an Outperform at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2508175688","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508175688?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:35","pubTimestamp":1738618547,"startTime":"0","endTime":"0","summary":"Wolfe Research initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating. Published first on TheFly – the ultimate source for real-tim...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-initiated-with-an-outperform-at-wolfe-research?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-initiated-with-an-outperform-at-wolfe-research?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"gpt_icon":0},{"id":"2506513319","title":"Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2506513319","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506513319?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:00","pubTimestamp":1738069200,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Jan.  28, 2025  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/28/3016303/0/en/Zenas-BioPharma-to-Present-at-the-Guggenheim-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4011","BK4139","SMID"],"gpt_icon":0},{"id":"2492395883","title":"Zenas BioPharma initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2492395883","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492395883?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:25","pubTimestamp":1734434721,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of Zenas BioPharma  with a Buy rating and $30 price target The company’s lead autoimmune therapy, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc gamma receptor IIb, FcgammaRIIb, broadly present on B cell lineage, the analyst tells investors in a research note. The firm believes obexelimab represents an autoimmune franchise molecule with the potential for B cell therapeutic differentiation.Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks. Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley. Zenas BioPharma completed targeted enrollment of Phase 3 INDIGO trial. Zenas BioPharma initiated with a Buy at Rodman & Renshaw","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CelDdPDqWVkcG2SiBC__kg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c4f6c07e08d4829fbea65fa26099a197","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CelDdPDqWVkcG2SiBC__kg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c4f6c07e08d4829fbea65fa26099a197"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/zenas-biopharma-initiated-buy-h-112521565.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zenas-biopharma-initiated-buy-h-112521565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","BK4534","BK4139","BK4516","LU1668664300.SGD","BK4127","LU0006306889.USD","LU0314104364.USD","LU1720051108.HKD","BK4585","LU0267386448.USD","LU0098860793.USD","LU2089283258.USD","LU2357305700.SGD","LU1363072403.SGD","LU1720051017.SGD","LU1074936037.SGD","LU1989772840.SGD","LU0971096721.USD","IE00BZ1G4Q59.USD","LU2111349929.HKD","LU1162221912.USD","LU0158827948.USD","LU2089284900.SGD","LU0320765646.SGD","IE00BKVL7J92.USD","LU0106261372.USD","LU2028103732.USD","LU0158827781.USD","BK4588","LU2023251221.USD","LU1548497426.USD","LU1989772923.USD","LU2271345857.HKD","ZBIO","LU0225283273.USD","BK4581","LU0106831901.USD"],"gpt_icon":0},{"id":"2491469843","title":"HC Wainwright Initiates Zenas BioPharma at Buy With $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2491469843","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491469843?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:48","pubTimestamp":1734353309,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (ZBIO) has an average rating of buy and mean price target of $34.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO"],"gpt_icon":0},{"id":"2491569865","title":"Zenas BioPharma Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2491569865","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491569865?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:39","pubTimestamp":1734352740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2024 07:39 ET (12:39 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2491669791","title":"Zenas Biopharma, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2491669791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491669791?lang=en_us&edition=fundamental","pubTime":"2024-12-16 19:19","pubTimestamp":1734347942,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nAZN2UG6OQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2490877852","title":"Zenas BioPharma Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2490877852","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490877852?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:33","pubTimestamp":1733923980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2024 08:33 ET (13:33 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"gpt_icon":0},{"id":"2490856417","title":"Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2490856417","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490856417?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:35","pubTimestamp":1733920537,"startTime":"0","endTime":"0","summary":"Morgan Stanley lowered the firm’s price target on Zenas BioPharma (ZBIO) to $35 from $40 and keeps an Overweight rating on the shares. The firm upd...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-price-target-lowered-to-35-from-40-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-price-target-lowered-to-35-from-40-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"gpt_icon":0},{"id":"2490832168","title":"Zenas Biopharma Inc : Morgan Stanley  Cuts Target Price to $35.00 From $40.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2490832168","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490832168?lang=en_us&edition=fundamental","pubTime":"2024-12-11 18:51","pubTimestamp":1733914273,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nAZN2T1VCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2490832787","title":"Strategic Shift and Positive Outlook Justify Buy Rating for Zenas BioPharma, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2490832787","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490832787?lang=en_us&edition=fundamental","pubTime":"2024-12-11 18:47","pubTimestamp":1733914059,"startTime":"0","endTime":"0","summary":"In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on Zenas BioPharma, Inc. (ZBIO – Research Report), with a pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/strategic-shift-and-positive-outlook-justify-buy-rating-for-zenas-biopharma-inc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/strategic-shift-and-positive-outlook-justify-buy-rating-for-zenas-biopharma-inc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"gpt_icon":0},{"id":"2483876940","title":"Zenas BioPharma’s Promising Pipeline and Strategic Moves Earn Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2483876940","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483876940?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:57","pubTimestamp":1731585431,"startTime":"0","endTime":"0","summary":"Zenas BioPharma, Inc. (ZBIO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vikram Pur...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/zenas-biopharmas-promising-pipeline-and-strategic-moves-earn-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/zenas-biopharmas-promising-pipeline-and-strategic-moves-earn-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"gpt_icon":0},{"id":"2482706662","title":"Zenas BioPharma reports Q3 EPS ($5.02), consensus ($9.33)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482706662","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482706662?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:33","pubTimestamp":1731414817,"startTime":"0","endTime":"0","summary":"“In the third quarter, we successfully completed our initial public offering, providing capital to fund our growth strategy for the Company and exp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-reports-q3-eps-5-02-consensus-9-33?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-reports-q3-eps-5-02-consensus-9-33?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"gpt_icon":0},{"id":"2482703370","title":"Press Release: Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2482703370","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482703370?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:10","pubTimestamp":1731413400,"startTime":"0","endTime":"0","summary":"-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy-. -Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related Disease -. -Advancing multiple obexelimab Phase 2 and Phase 3 clinical trials with results expected throughout 2025-. WALTHAM, Mass., Nov. 12, 2024  -- Zenas BioPharma, Inc.  , a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today reported financial results for the third quarter ended September 30, 2024, and provided recent corporate updates.\"In the third quarter, we successfully completed our initial public offering, providing capital to fund our growth strategy for the Company and expand the clinical development of our lead product candidate, obexelimab,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139","SLE","BK4077"],"gpt_icon":0},{"id":"2482703367","title":"Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482703367","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482703367?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:05","pubTimestamp":1731413100,"startTime":"0","endTime":"0","summary":"-INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov.  12, 2024  (GLOBE NEWSWIRE) -- Zenas BioPharm","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2978935/0/en/Zenas-BioPharma-Completes-Targeted-Enrollment-of-the-Phase-3-INDIGO-Trial-of-Obexelimab-in-Immunoglobulin-G4-Related-Disease-IgG4-RD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2481905123","title":"Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2481905123","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481905123?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:05","pubTimestamp":1730981100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass, Nov.  07, 2024  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/07/2976535/0/en/Zenas-BioPharma-to-Participate-in-Upcoming-Healthcare-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","ZBIO","HCSG","BK4139"],"gpt_icon":0},{"id":"2481419574","title":"Zenas BioPharma initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2481419574","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481419574?lang=en_us&edition=fundamental","pubTime":"2024-11-05 19:40","pubTimestamp":1730806843,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw initiated coverage of Zenas BioPharma (ZBIO) with a Buy rating and $34 price target Published first on TheFly – the ultimate sourc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-initiated-with-a-buy-at-rodman-renshaw?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-initiated-with-a-buy-at-rodman-renshaw?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2024/09","expectedEps":13,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-5.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.7143,"buy":0.2857,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.7143,"analysts":7,"updateTime":1742529600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZBIO","date":"2025-04-28","current":-2.667907,"percent":0.545455,"low":-19.592941,"twenty":-13.049152,"median":-2.91955,"eighty":-2.262259,"high":-1.802568,"avg":-6.01338,"sd":5.390609,"marketCap":418829346},"quantilePoints":[{"date":"2024-09-13","current":-8.364044,"twenty":-11.189626,"median":-10.130033,"eighty":-9.07044,"marketCap":457989962},{"date":"2024-09-20","current":-12.731934,"twenty":-12.968841,"median":-12.731934,"eighty":-9.523082,"marketCap":697162515},{"date":"2024-09-27","current":-12.564791,"twenty":-13.484804,"median":-12.909978,"eighty":-12.029776,"marketCap":688010267},{"date":"2024-10-04","current":-14.275075,"twenty":-13.747873,"median":-12.811872,"eighty":-12.31335,"marketCap":781660299},{"date":"2024-10-11","current":-13.008553,"twenty":-13.941177,"median":-13.027627,"eighty":-12.397648,"marketCap":712309358},{"date":"2024-10-18","current":-16.373229,"twenty":-14.273549,"median":-13.29848,"eighty":-12.477586,"marketCap":896548905},{"date":"2024-10-25","current":-17.845752,"twenty":-15.022781,"median":-13.503182,"eighty":-12.59822,"marketCap":977179818},{"date":"2024-10-31","current":-16.022265,"twenty":-16.022265,"median":-13.891034,"eighty":-12.731934,"marketCap":877331175},{"date":"2024-11-08","current":-15.961228,"twenty":-15.961228,"median":-14.267446,"eighty":-12.811872,"marketCap":873988961},{"date":"2024-11-15","current":-6.06727,"twenty":-16.022265,"median":-14.202594,"eighty":-12.564791,"marketCap":782495852},{"date":"2024-11-22","current":-3.382919,"twenty":-15.961228,"median":-13.807463,"eighty":-11.896022,"marketCap":436298426},{"date":"2024-11-29","current":-3.729636,"twenty":-15.955124,"median":-13.496851,"eighty":-6.578437,"marketCap":481014835},{"date":"2024-12-06","current":-3.402361,"twenty":-15.898664,"median":-13.178717,"eighty":-4.851473,"marketCap":438805888},{"date":"2024-12-13","current":-2.997318,"twenty":-15.744546,"median":-13.008553,"eighty":-3.729636,"marketCap":386567092},{"date":"2024-12-20","current":-3.162575,"twenty":-15.636205,"median":-12.771903,"eighty":-3.606503,"marketCap":407880521},{"date":"2024-12-27","current":-3.256545,"twenty":-15.585849,"median":-12.510288,"eighty":-3.394584,"marketCap":419999921},{"date":"2025-01-03","current":-2.91955,"twenty":-15.427152,"median":-12.339512,"eighty":-3.24488,"marketCap":376537243},{"date":"2025-01-10","current":-3.007039,"twenty":-15.189107,"median":-10.412935,"eighty":-3.188498,"marketCap":387820823},{"date":"2025-01-17","current":-2.520987,"twenty":-15.022781,"median":-6.676265,"eighty":-3.159983,"marketCap":325134267},{"date":"2025-01-24","current":-2.715408,"twenty":-14.870188,"median":-6.06727,"eighty":-3.071846,"marketCap":350208890},{"date":"2025-01-31","current":-2.469142,"twenty":-14.351372,"median":-4.794107,"eighty":-2.968155,"marketCap":318447701},{"date":"2025-02-07","current":-2.54367,"twenty":-14.313224,"median":-3.888412,"eighty":-2.841781,"marketCap":328059640},{"date":"2025-02-14","current":-2.313605,"twenty":-14.275075,"median":-3.716674,"eighty":-2.653842,"marketCap":298388004},{"date":"2025-02-21","current":-2.530708,"twenty":-14.268972,"median":-3.643766,"eighty":-2.622086,"marketCap":326387998},{"date":"2025-02-28","current":-2.141867,"twenty":-14.163683,"median":-3.476889,"eighty":-2.54367,"marketCap":276238754},{"date":"2025-03-07","current":-2.35573,"twenty":-14.007233,"median":-3.332693,"eighty":-2.517747,"marketCap":303820838},{"date":"2025-03-14","current":-2.324434,"twenty":-13.840892,"median":-3.246824,"eighty":-2.465902,"marketCap":364908203},{"date":"2025-03-21","current":-2.26852,"twenty":-13.569102,"median":-3.188498,"eighty":-2.360915,"marketCap":356130342},{"date":"2025-03-28","current":-2.138053,"twenty":-13.499383,"median":-3.165816,"eighty":-2.351842,"marketCap":335648668},{"date":"2025-04-04","current":-2.076814,"twenty":-13.408148,"median":-3.159335,"eighty":-2.284767,"marketCap":326034820},{"date":"2025-04-11","current":-1.80523,"twenty":-13.315978,"median":-3.071846,"eighty":-2.26652,"marketCap":283399498},{"date":"2025-04-17","current":-2.21793,"twenty":-13.154764,"median":-2.997318,"eighty":-2.257224,"marketCap":348188468},{"date":"2025-04-25","current":-2.657256,"twenty":-13.051602,"median":-2.943853,"eighty":-2.261324,"marketCap":417157373},{"date":"2025-04-28","current":-2.667907,"twenty":-13.049152,"median":-2.91955,"eighty":-2.262259,"marketCap":418829346}],"updateTime":1746000269204}}}